385 related articles for article (PubMed ID: 29126352)
1. Fatal myocarditis and rhabdomyolysis induced by nivolumab during the treatment of type B3 thymoma.
Chen Q; Huang DS; Zhang LW; Li YQ; Wang HW; Liu HB
Clin Toxicol (Phila); 2018 Jul; 56(7):667-671. PubMed ID: 29126352
[TBL] [Abstract][Full Text] [Related]
2. Late-Onset Fulminant Myocarditis With Immune Checkpoint Inhibitor Nivolumab.
Yamaguchi S; Morimoto R; Okumura T; Yamashita Y; Haga T; Kuwayama T; Yokoi T; Hiraiwa H; Kondo T; Sugiura Y; Watanabe N; Kano N; Kohno K; Fukaya K; Sawamura A; Yokota K; Ishii H; Nakaguro M; Akiyama M; Murohara T
Can J Cardiol; 2018 Jun; 34(6):812.e1-812.e3. PubMed ID: 29801747
[TBL] [Abstract][Full Text] [Related]
3. Myocarditis in a patient treated with Nivolumab and PROSTVAC: a case report.
Monge C; Maeng H; Brofferio A; Apolo AB; Sathya B; Arai AE; Gulley JL; Bilusic M
J Immunother Cancer; 2018 Dec; 6(1):150. PubMed ID: 30563577
[TBL] [Abstract][Full Text] [Related]
4. PD-1 inhibitor-associated severe myasthenia gravis with necrotizing myopathy and myocarditis.
So H; Ikeguchi R; Kobayashi M; Suzuki M; Shimizu Y; Kitagawa K
J Neurol Sci; 2019 Apr; 399():97-100. PubMed ID: 30798111
[No Abstract] [Full Text] [Related]
5. Acute fatal myocarditis after a single dose of anti-PD-1 immunotherapy, autopsy findings: a case report.
Hardy T; Yin M; Chavez JA; Ivanov I; Chen W; Nadasdy T; Brodsky SV
Cardiovasc Pathol; 2020; 46():107202. PubMed ID: 32062109
[TBL] [Abstract][Full Text] [Related]
6. Severe colitis after PD-1 blockade with nivolumab in advanced melanoma patients: potential role of Th1-dominant immune response in immune-related adverse events: two case reports.
Yoshino K; Nakayama T; Ito A; Sato E; Kitano S
BMC Cancer; 2019 Oct; 19(1):1019. PubMed ID: 31664934
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of anti-programmed death-ligand 1 (PD-L1) antibody (Avelumab) treatment in advanced thymoma.
Rajan A; Heery CR; Thomas A; Mammen AL; Perry S; O'Sullivan Coyne G; Guha U; Berman A; Szabo E; Madan RA; Ballester LY; Pittaluga S; Donahue RN; Tsai YT; Lepone LM; Chin K; Ginty F; Sood A; Hewitt SM; Schlom J; Hassan R; Gulley JL
J Immunother Cancer; 2019 Oct; 7(1):269. PubMed ID: 31639039
[TBL] [Abstract][Full Text] [Related]
8. Fatal association of fulminant myocarditis and rhabdomyolysis after immune checkpoint blockade.
Tomoaia R; Beyer RȘ; Pop D; Minciună IA; Dădârlat-Pop A
Eur J Cancer; 2020 Jun; 132():224-227. PubMed ID: 32336614
[No Abstract] [Full Text] [Related]
9. Fatal myocarditis and rhabdomyositis in a patient with stage IV melanoma treated with combined ipilimumab and nivolumab.
Saibil SD; Bonilla L; Majeed H; Sotov V; Hogg D; Chappell MA; Cybulsky M; Butler MO
Curr Oncol; 2019 Jun; 26(3):e418-e421. PubMed ID: 31285688
[TBL] [Abstract][Full Text] [Related]
10. Cardiorenal complications of immune checkpoint inhibitors.
Sury K; Perazella MA; Shirali AC
Nat Rev Nephrol; 2018 Sep; 14(9):571-588. PubMed ID: 30013100
[TBL] [Abstract][Full Text] [Related]
11. Fatal adverse events in two thymoma patients treated with anti-PD-1 immune check point inhibitor and literature review.
Konstantina T; Konstantinos R; Anastasios K; Anastasia M; Eleni L; Ioannis S; Sofia A; Dimitris M
Lung Cancer; 2019 Sep; 135():29-32. PubMed ID: 31446999
[TBL] [Abstract][Full Text] [Related]
12. [Third degree atrio-ventricular blockade during a myocarditis occurring under anti-PD1 : Case report and literature review].
Prevel R; Colin G; Calès V; Renault PA; Mazieres J
Rev Med Interne; 2020 Apr; 41(4):284-288. PubMed ID: 31983550
[TBL] [Abstract][Full Text] [Related]
13. Acute Lymphocytic Myocarditis With Anti-PD-1 Antibody Nivolumab.
Tadokoro T; Keshino E; Makiyama A; Sasaguri T; Ohshima K; Katano H; Mohri M
Circ Heart Fail; 2016 Oct; 9(10):. PubMed ID: 27650418
[No Abstract] [Full Text] [Related]
14. Multi-organ Immune-Related Adverse Event Is a Risk Factor of Immune Checkpoint Inhibitor-Associated Myocarditis in Cancer Patients: A Multi-center Study.
Xie X; Wang L; Li Y; Xu Y; Wu J; Lin X; Lin W; Mai Q; Chen Z; Zhang J; Xie Z; Qin Y; Liu M; Lu M; Luo B; Zhou C
Front Immunol; 2022; 13():879900. PubMed ID: 35924238
[TBL] [Abstract][Full Text] [Related]
15. Fatal Simultaneous Multi-organ Failure Following Pembrolizumab Treatment for Refractory Thymoma.
Hyun JW; Kim GS; Kim SH; Cho JY; Kim HJ; Lee GK; Kim HJ; Kwon SU
Clin Lung Cancer; 2020 Mar; 21(2):e74-e77. PubMed ID: 31718909
[No Abstract] [Full Text] [Related]
16. Immune-Therapy-Related Toxicity Events and Dramatic Remission After a Single Dose of Pembrolizumab Treatment in Metastatic Thymoma: A Case Report.
Shen L; Chen H; Wei Q
Front Immunol; 2021; 12():621858. PubMed ID: 33936037
[TBL] [Abstract][Full Text] [Related]
17. Abatacept for Severe Immune Checkpoint Inhibitor-Associated Myocarditis.
Salem JE; Allenbach Y; Vozy A; Brechot N; Johnson DB; Moslehi JJ; Kerneis M
N Engl J Med; 2019 Jun; 380(24):2377-2379. PubMed ID: 31189043
[No Abstract] [Full Text] [Related]
18. [Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers].
Duruisseaux M; Rouquette I; Adam J; Cortot A; Cazes A; Gibault L; Damotte D; Lantuejoul S
Ann Pathol; 2017 Feb; 37(1):61-78. PubMed ID: 28162296
[TBL] [Abstract][Full Text] [Related]
19. Nivolumab-associated myositis myocarditis and myasthenia and anti-striated muscle antibodies.
Fazal M; Prentice DA; Kho LK; Fysh E
Intern Med J; 2020 Aug; 50(8):1003-1006. PubMed ID: 33306231
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of nivolumab for patients with pre-treated type B3 thymoma and thymic carcinoma: results from the EORTC-ETOP NIVOTHYM phase II trial.
Girard N; Ponce Aix S; Cedres S; Berghmans T; Burgers S; Toffart AC; Popat S; Janssens A; Gervais R; Hochstenbag M; Silva M; Burger IA; Prosch H; Stahel R; Xenophontos E; Pretzenbaher Y; Neven A; Peters S
ESMO Open; 2023 Jun; 8(3):101576. PubMed ID: 37285717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
